Excluded studies

Excluded studies

Study reference

Reason for exclusion

Astrup A, Carraro R, Finer N et al. (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog liraglutide International Journal of Obesity 36 (6), 843–54

Study not prioritised (not the best available evidence: phase II dose finding study)

Astrup A, Rössner S, Van Gaal L et al. (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 (9701), 1606–16

Study not prioritised (not the best available evidence: phase II dose finding study)

Wadden TA, Hollander P, Klein S et al. (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study International Journal of Obesity 37 (11), 1443–51

Study not prioritised (not the best available evidence: based on participant selection and number of participants in study)

Kolotkin RL, Fujioka K, Wolden M L et al. (2016) Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management Clinical Obesity 6 (4), 233–42

Study not prioritised (not best available evidence: additional analysis from Pi-Sunyer et al. 2015 study)

Lean ME. J, Carraro R, Finer N et al. (2014) Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. International Journal of Obesity38 (5), 689–97

Study not prioritised (not the best available evidence: results from phase II dose finding study)